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Introduction: Transforming growth factor (TGF)-β and interleukin (IL)-13 play a crucial role in the pathogenesis of
systemic sclerosis (SSc), partly through activation of collagen production that leads to fibrosis. The aim of the
present study was to determine whether TFG-β alters IL-13 production in T lymphocytes from patients with SSc
from that seen in those of healthy donors.
Methods: IL-13 mRNA and protein synthesis under TFG-β exposure was measured in circulating T lymphocytes from
healthy donors and patients with SSc and also in the Jurkat Th2 T-cell line, using quantitative real-time PCR and
fluorescence-activated cell sorting analysis, respectively. The involvement of Smad and GATA-3 transcription factors was
assessed by using specific inhibitors and small interfering RNA, and the binding capacity of GATA-3 to the IL-13 gene
promoter was evaluated by chromatin immunoprecipitation assay.
Results: TGF-β induced a significant decrease in IL-13 mRNA and protein levels in lymphocytes from healthy donors
(mean [±SD] inhibition of 30 %± 10 % and 20 %± 7 %, respectively; p< 0.05). In contrast, TGF-β promoted a significant
increase in IL-13 mRNA levels and IL-13 synthesis by CD4+ and CD8+ T-cell subtypes from patients with SSc, with
respective increases of 2.4 ± 0.3-fold, 1.6 ± 0.05-fold and 2.7 ± 0.02-fold. The involvement of the Smad signaling pathway
and upregulation of GATA-3 binding capacity on the IL-13 promoter in lymphocytes from patients with SSc contributed to
the effect of TGF-β on IL-13 production.
Conclusions: These results demonstrate that TGF-β upregulates IL-13 synthesis through GATA-3 expression in the T
lymphocytes of patients with SSc, confirming that the GATA-3 transcription factor can be regarded as a novel therapeutic
target in patients with SSc.Introduction
Systemic sclerosis (SSc) is a systemic autoimmune and
inflammatory disease with a heterogeneous clinical
presentation characterized by progressive fibrosis of the
skin and internal organs, vascular damage, autoantibody
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from patients with scleroderma have provided direct evi-
dence of the involvement of cytokines in the inflammatory
and fibrotic processes of SSc [3, 4]. Particularly, elevated
levels of two type 2 helper (Th2) T-cell–produced cytokines
(transforming growth factor [TGF]-β and interleukin [IL]-
13) have been observed in the serum and tissue of patients
with SSc [5, 6], and these cytokines have been shown to be
able to induce skin fibrosis [7–10].
TGF-β belongs to the TGF-β superfamily containing
three homologous isoforms in mammals (TGF-β1, TGF-β2
and TGF-β3) encoded by different genes [11]. TGF-β1 isticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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monocytes and tissue macrophages in the immune system
[12]. The TGF-β1 signaling pathway mediates its biological
functions via binding to type II TGF-β transmembrane re-
ceptor (TGFβRII). TGFβRII recruits and phosphorylates
the type I receptor TGFβRI, which belongs to the activin
receptor-like kinase (ALK) family, leading to cell signaling
initiation via ALK5 involvement [11]. Upon phosphoryl-
ation by ALK5, receptor-regulated Smads R-Smad2 and
R-Smad3 associate with co-Smad4 and translocate into the
nucleus to bind to Smad-binding element in association
with a large number of other transcription factors [13, 14].
This leads to transcriptional regulation of target genes,
including those that encode extracellular matrix (ECM)
proteins such as collagens I and III [15–17]. Besides the
Smad canonical pathway, TGF-β1 is also able to activate
Smad-independent signaling pathways, such as Ras- extra-
cellular signal-regulated kinase (ERK), c-Jun N-terminal kin-
ase (JNK), p38, mitogen-activated protein kinases (MAPKs)
and phosphatidylinositol 3-kinase-Akt [15, 16, 18, 19]. In
addition, TGF-β1 is one of the most potent profibrotic cy-
tokines able to upregulate ECM proteins, downregulate
matrix metalloproteinases (MMPs), induce myofibroblast
differentiation and modulate the expression of various
cytokine receptors, including its own [14]. The literature
contains evidence that activation of the p38 pathway
downstream to TGF-β receptors is also involved in the
regulation of Th2 cytokine synthesis, including IL-4
and IL-13 [20, 21]. Indeed, overexpression of TGF-β1–
dependent genes has been observed in biopsy specimens
of skin lesions from patients with scleroderma [22].
TGF-β1 is also a potent immunomodulator, regulating
T-cell proliferation, differentiation and survival in healthy
humans [12, 23] by downregulating IL-2 transcription via
Smad3 [24] or by directly targeting cell cycle regulators
such as cyclin-dependent kinase inhibitors (p15, p27 or
p21), c-Myc, cyclin D2 and cyclin E [25]. TGF-β1 can also
inhibit Th1 and Th2 differentiation by repressing ex-
pression of the T-bet [26] and GATA-3 [27] transcription
factors, respectively. It also induces FoxP3-expressing
CD4+CD25+ regulatory T cells to indirectly influence T-
cell activation [28].
Besides TGF-β, other crucial fibrosis inductors have
been described, including IL-13 and IL-4. Both are pro-
duced by activated Th2 T cells and share many func-
tional activities by using the same IL-4 receptor α-chain
[29, 30]. Inhibition of IL-4 and IL-13 in an independent
way identified IL-13 as the dominant effector cytokine of
fibrosis [31]. IL-13 can promote tissue fibrosis by direct
fibroblast activation, as well as by indirect pathways, via
TGF-β production stimulation. IL-13 binds the IL-13 re-
ceptor α-chain 2 (IL-13Rα2) that induces upregulation
of TGF-β promoter activities and uses activator protein
AP-1 as a signaling pathway distinct from the one usedby IL-4, leading to an increase in its own fibrogenic po-
tential [9, 32]. Moreover, IL-13 induces the production
of latent TGF-β1 from macrophages and TGF-β1 activa-
tion through upregulation of MMP9 expression, leading
to lung fibrosis [9]. A fibrogenesis pathway that is IL-
13–dependent but TGF-β1–independent has also been
reported [33]. The importance of IL-13 in SSc suscepti-
bility has been shown by genetic studies involving poly-
morphisms in the IL-13 [34] and IL-13Rα2 [35] genes,
and many studies support the role of IL-13 in SSc patho-
genesis [36–39]. Recently, Fuschiotti et al. showed that
IL-13–producing CD8+ T cells are directly involved in
modulating dermal fibrosis in SSc [10], confirming the
importance of IL-13 in the pathogenesis of SSc dermal
fibrosis.
Upregulation of IL-13 production with increased acti-
vation of GATA-3 has been shown in naïve CD8+ T cells
from patients with SSc [40]. GATA-3 is the dominant
transcription factor able to regulate Th2 differentiation
and IL-13 production by Th2 effector T cells [41], and,
although GATA-3 can be regulated by TGF-β, IL-13
regulation by TGF-β has not been completely studied in
SSc.
We designed the present study to analyze whether the
multifunctional growth factor TGF-β1 is able to modulate
IL-13 synthesis in T cells and which signaling pathway is
involved by using specific inhibitors of the TGF-β receptor
kinase ALK5 at the top of the signaling pathway as well as
the Smad and p38-MAPK pathways. Our results show
that TGF-β significantly upregulates IL-13 synthesis in
T lymphocytes from patients with SSc, whereas it acts as a
negative modulator of IL-13 synthesis in T lymphocytes
from healthy donors, via respective up- and downregulation
of GATA-3 transcription factor activity.
Methods
Study subjects
Sixteen patients (eleven females) with diffuse cutaneous
SSc were recruited from the Internal Medicine and Vascu-
lar Disease Unit of St. Louis Hospital (Paris, France). All
patients fulfilled the classification criteria for SSc proposed
by the American College of Rheumatology [42] and were
included before having received any treatment. At the
time of sampling, their median age was 48.5 (range,
25–78) years and median modified Rodnan skin score was
29.5 (range, 14–51). Blood samples from 12 healthy volun-
teers (6 females) from the Etablissement Français du Sang
were used as controls (median [range] age, 34 (24–55)
years). Patients and healthy donors gave their written in-
formed consent after the study received approval by the
local ethics committee. Because of the limitations of blood
sample availability, some of the experiments were per-
formed using T lymphocytes from only some of the pa-
tients with SSc or some of the healthy volunteers, as
Baraut et al. Arthritis Research & Therapy  (2015) 17:196 Page 3 of 15indicated. The Jurkat Th2 T-cell line (clone E6-1) was
purchased from the European Collection of Animal Cell
Cultures (Salisbury, UK).
Cell cultures
Peripheral blood mononuclear cells (PBMCs) were
isolated by Ficoll-Hypaque centrifugation (Amersham
Pharmacia Biotech, Little Chalfont, UK), and peripheral
blood lymphocytes (PBLs) were isolated from PBMCs
by elimination of monocytes by adhesion for 2 h. All
cultures were grown at 37 °C with 5 % CO2 at 0.2 × 10
6
cells/ml in complete RPMI 1640 medium (Gibco; Life
Technologies, Carlsbad, CA, USA) supplemented with
10 % fetal calf serum (FCS), 1 % penicillin-streptomycin
and 1 % N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid (HEPES).
Study design
PBLs from patients with SSc and healthy donors were cul-
tured for 5 days on plates previously coated with anti-CD3
(clone HIT3a, 2 μg/ml; BD Pharmingen, San Diego, CA,
USA) antibody at the concentration of 0.5 × 106 cells/ml
in complete RPMI 1640 medium supplemented with sol-
uble anti-CD28 (clone CD28.2, 1 μg/ml; BD Pharmingen)
antibody and IL-2 (20 U/ml; PeproTech, Rocky Hill, NJ,
USA). At the sixth day, cells were stimulated for the last
4 h with a combination of phorbol 12-myristate 13-acetate
(10 μg/ml; Sigma-Aldrich, St. Louis, MO, USA) and
ionomycin (1 μM; Sigma-Aldrich) in the presence or ab-
sence of the optimal concentration of 5 ng/ml TGF-β1
(PeproTech), named TGF-β hereafter, in 0.5 % FCS-
containing RPMI 1640 medium with or without a 1-h
preincubation with specific inhibitors (SB431542 from
Sigma-Aldrich; SB203580 or SIS3 from Calbiochem, San
Diego, CA, USA). Jurkat T cells were cultured in 0.5 %
FCS-containing medium for 16 h before addition of 5 ng/ml
TGF-β for 30 min or 4 h.
Flow cytometry
IL-13 production was determined by intracellular stain-
ing using phycoerythrin (PE)-labeled anti-human IL-13
antibody (clone JES10-5A2; BD Biosciences, San Jose,
CA, USA). HiCK-2 human cytokine positive control cells
(BD Pharmingen) were used as a positive control for
IL-13 staining. Cell phenotype was assessed by staining
with specific association of fluorescein isothiocyanate
(FITC)-CD4, allophycocyanin (APC)-CD3 and PE-IL-13
antibodies or association of FITC-CD8, APC-CD3 and
PE-IL-13 antibodies (all from BD Biosciences). Antibody
isotypes (BD Biosciences) were selected to match these
specific antibodies. Before intracellular staining, cells
were incubated with BD GolgiStop (BD Pharmingen) for
the last 4 h of stimulation, then fixed for 1 h at 4 °C in
phosphate-buffered saline (PBS) containing 0.45 %formaldehyde before permeabilization for 15 min at 37 °C
in PBS containing 0.2 % Tween-20. After two PBS
washes, cells were incubated with PE isotype or PE-IL-
13 antibodies at optimal concentrations in PBS for
30 min at 4 °C in the dark and then washed in PBS with
2 % FCS. Cells were next incubated with FITC or APC
isotypes or FITC-CD4 or FITC-CD8 and APC-CD3
antibodies for membrane staining for 20 min at 4 °C in
the dark and finally fixed with 1 % formaldehyde.
Surface and intracellular expression was quantified
using a FACSCalibur flow cytometer (BD Biosciences)
with gate established on forward scatter and side scat-
ter lymphocyte areas. Unstained cells or cells stained
with isotype-matched antibodies were used to indicate
nonspecific signals and establish the positive limits.
Data were analyzed with Kaluza software (Beckman
Coulter, Brea, CA, USA).
Quantitative RT-PCR
Total RNA was extracted using an RNeasy™ Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. DNase I treatment (25 U, 15 min) of
total RNA was performed to eliminate genomic contam-
ination of the RNA samples. One microgram of total
RNA was used for first-strand cDNA synthesis using a
RT-PCR kit (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. RT-PCR was performed
with an ABI PRISM 7300 instrument (Applied Biosystems,
Foster City, CA, USA) using SYBR Green PCR core re-
agents (Applied Biosystems). The β-glucuronidase (GUS)
housekeeping gene expression was used as reference to
normalize mRNA levels for each sample. The sequence of
the forward primer for IL-13 mRNA was 5′-CGAGAA
GACCCAGAGGATGCT-3′, and that of the reverse pri-
mer was 5′-ACTGCCCAGCTGAGACCTTGT-3′. For
TGF-β mRNA, the forward primer was 5′- GGGAAA
TTGAGGGCTTTCG-3′ and the reverse primer was
5′- GAACCCGTTGATGTCCACTTG-3′. For GATA-3
mRNA, the forward primer was 5′- TGCGGGCTCTA
TCACAAAATG-3′ and the reverse primer was 5′- GC
CTTCGCTTGGGCTTAAT-3′. The forward primer for
GUS mRNA was 5′- GAAAATATGTGGTTGGAGAG
CTCATT-3′ and the reverse primer was 5′- CCGAG
TGAAGATCCCCTTTTTA-3′. The conditions for the
one-step RT-PCR were as follows: 5 min at 95 °C, then
35 cycles of amplification at 95 °C for 30 s and 30 s at
55 °C, and finally 1 min at 72 °C and 10 min at 72 °C. Each
assay was run in duplicate. All samples were normalized to
GUS. Quantification of the target gene expression was
done using the comparative cycle threshold (Ct) method
according to the manufacturer’s instructions (Applied
Biosystems). An average Ct was calculated for the duplicate
reactions and normalized to housekeeping gene GUS
(ΔCt = Ct sample −Ct GUS).
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Jurkat T cells (5 × 106) were stimulated with TGF-β for
4 h, followed by the addition of actinomycin D (3 μg/ml)
to halt ongoing transcription. After 1, 3 and 5 h, cells
were pelleted and total RNA was extracted using
RNeasy™ Mini Kit for further quantification of IL-13 and
GUS mRNA levels by quantitative RT-PCR (qRT-PCR).
Transient cell transfections and reporter assays
Two million Jurkat T cells were electroporated with 2 μg
of pGL3 2666-bp IL-13 promoter construct/Luciferase
(2666 bp-IL13-Lux) or 2 μg of (CAGA)9-Lux/Luciferase
(cytomegalovirus [CMV] Smad3/4-specific reporter con-
struct [43]), using the Cell Line Nucleofector Kit (Lonza,
Cologne, Germany). Empty pGL3- and CMV-Lux plas-
mids (2 μg) were transfected as respective controls.
Transfection efficiency was estimated to 50–60 % by using
cotransfection of a green fluorescent protein expression
vector and cytometric analysis (data not shown). Firefly
and Renilla luciferase activities were used for norma-
lization using the Dual-Luciferase Reporter Assay System
and a GloMax 20/20 luminometer (Promega, Madison,
WI, USA).
Western blot analysis
Nuclear and cytoplasmic protein extracts were isolated
using a small-scale preparation (Promega) and stored
at −80 °C until use. The protein concentration in the
cytoplasmic or nuclear extracts was determined using
a Bradford assay (Bio-Rad Laboratories, Hercules, CA,
USA). Fifty micrograms of protein extracts were denatured
by heating at 95 °C for 3 min before resolution by SDS-
PAGE, electrotransferred to Hybond enhanced chemilu-
minescence nitrocellulose filters (Amersham Biosciences,
Little Chalfont, UK) and immunoblotted with either anti–
phospho-Smad3 (clone EP823Y) and anti-Smad3 (clone
EP568Y) antibodies from EMD Millipore (Billerica, MA,
USA), anti-GATA-3 (clone HG3-31) or anti-β-actin anti-
bodies from Santa Cruz Biotechnology (Santa Cruz, CA,
USA), all at 1:1000 concentration in PBS/5 % nonfat milk,
for 1 h. After washing, filters were incubated with
horseradish peroxidase–conjugated anti-rabbit or anti-
mouse secondary antibodies (Santa Cruz Biotechnology).
An enhanced chemiluminescence system (Amersham
Biosciences) was used for detection. Equal protein loading
was confirmed by using monoclonal β-actin blots (Sigma-
Aldrich). Densitometry was done using the Imager FX
System (Bio-Rad Laboratories) and analyzed using ImageJ
software (National Institutes of Health, Bethesda, MD,
USA).
Chromatin immunoprecipitation
After fixation in 1 % formaldehyde, T cells (1 × 107) were
lysed for 5 min in 50 mM Tris buffer (pH 8) containing0.2 mM ethylenediaminetetraacetic acid (EDTA), 0.1 %
Nonidet P (NP)-40 and 10 % glycerol supplemented with
anti-protease cocktail (Roche Life Science, Indianapolis,
IN, USA). Nuclei were resuspended in 50 mM Tris buf-
fer with 1 % SDS and 5 mM EDTA. Chromatin was
sheared by sonication. After preclearing with protein A
beads (Santa Cruz Biotechnology), lysates were incubated
overnight at 4 °C with 1 μg/ml anti-GATA-3 (sc-269) or
mouse immunoglobulin G (IgG) antibodies (Santa Cruz
Biotechnology). Immune complexes were collected with
protein A, washed three times with high-salt buffer
(50 mM HEPES-KOH, 140 mM NaCl, 1 mM EDTA, 1 %
Triton X-100, 0.1 % sodium deoxycholate), twice with
low-salt buffer (10 mM Tris–HCl, 250 mM LiCl, 1 mM
EDTA, 0.5 % NP-40, 0.1 % sodium deoxycholate) and then
twice with Tris-EDTA (TE). Immune complexes were ex-
tracted in 1× TE buffer, and protein crosslinking was
reverted by heating at 65 °C for 5 h. DNA was then ex-
tracted by phenol-chloroform and precipitated by ethanol,
and a 1/20 fraction of the immunoprecipitated DNA was
used for qRT-PCR.
Statistical analysis
Given the non-Gaussian distribution of frequencies,
Wilcoxon rank-sum tests were used to compare dif-
ferences between the SSc patient group and the healthy
donor group. All tests were two-sided, and differences
were considered as significant at p < 0.05.
Ethical approval
This study was conducted with the approval of the ethics
committee of St. Louis Hospital (Paris, France).
Results
Opposite regulation of IL-13 production by TGF-β in T
lymphocytes from healthy donors and patients with SSc
The aim of the present study was to investigate the
effect of TGF-β on IL-13 mRNA and protein expression
in T lymphocytes from healthy donors and from patients
with SSc. PBLs were incubated with TGF-β for 4 h before
analysis. IL-13 mRNA production and IL-13 protein ex-
pression were measured by qRT-PCR and fluorescence-
activated cell sorting (FACS), respectively. Mean (±SD)
basal IL-13 mRNA levels were 0.94 ± 0.84 (n = 8) and
1.03 ± 0.82 (n = 10) in patients with SSc and in healthy
controls, respectively. No significant difference was de-
tected between the IL-13 baseline values in these two
groups. As shown in Fig. 1a, TGF-β induced a significant
decrease in IL-13 mRNA levels of PBLs from healthy
donors, with a mean inhibition of 30 ± 10 % (n = 8;
p < 0.001). The mean percentages of IL-13-producing CD4+
and CD8+ T cells in healthy donors reached 3.43 ± 0.6 %
and 1.28 ± 0.4 %, respectively. TGF-β induced a significant
decrease in the percentages of IL-13-producing CD4+ T
Fig. 1 Effect of transforming growth factor (TGF)-β on interleukin (IL)-13 production by T lymphocytes from healthy donors and patients with SSc.
Freshly isolated peripheral blood lymphocytes (PBLs) from healthy donors (n = 8) and patients with systemic sclerosis (SSc) (n = 10) were cultivated
with anti-CD3/anti-CD28 antibodies and IL-2 for 5 days, then stimulated with phorbol 12-myristate 13-acetate (P) + ionomycin (I) for 5 h and treated or
not with TGF-β for the last 4 h. a Levels of IL-13 mRNA measured by RT-PCR analysis and frequency of IL-13 cells in b and d CD4+ and c and e CD8+
T cells were quantified by intracellular staining by fluorescence-activated cell sorting (FACS) analysis. The results are presented as mean percentage
(±SD) of IL-13 expression measured in the presence of TGF-β (dark bars) relative to the respective IL-13 expression detected in the absence of TGF-β
(white bars). *p < 0.05; ***p < 0.001. Representative FACS histograms are from one representative healthy control (left panel) and one representative
patient (right panel) showing double staining of d CD4+IL-13+ and e CD8+IL-13+ cells gated on CD3+ T lymphocytes, previously treated or not with
TGF-β, as measured by intracellular IL-13 staining and surface expression of CD4 or CD8
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with mean inhibition of 20 ± 7 % and 25 ± 8 % (n = 8;
p < 0.05), respectively. In contrast (Fig. 1a), TGF-β induced
a significant increase in IL-13 mRNA levels in PBLs from
patients with SSc, with a mean fold increase of 2.4 ± 0.32
(n = 10, p < 0.05). Considering IL-13 protein levels in
T-cell subsets from patients with SSc, the mean percent-
ages of IL-13-producing CD4+ and CD8+ T cells were
3.86 ± 1.4 % and 1.3 ± 0.5 %, respectively. These levels
were not significantly different from those detected in
healthy donors, but TGF-β induced a significant increase
in the percentages of IL-13-producing CD4+ T cells
(Fig. 1b) and of IL-13-producing CD8+ T cells (Fig. 1c)
from patients with SSc, with respective mean fold
increases of 1.6 ± 0.05 and 2.7 ± 0.02 (n = 7; p < 0.05 and
p < 0.001, respectively). Fig. 1d and Fig. 1e show FACS dot
plots combining CD4+ or CD8+, respectively, and intracel-
lular IL-13 staining for one representative healthy donor(left panel) and for one representative patient with SSc
(right panel).
Molecular mechanisms involved in IL-13 synthesis in
response to TGF-β
To better understand the opposite IL-13 synthesis of T
lymphocytes from healthy individuals and patients with
SSc in response to TGF-β, the molecular pathways in-
volved in TGF-β effects were dissected first in normal T
lymphocytes and in Jurkat Th2 T-cell line. As observed
in Fig. 2a, TGF-β also induced a rapid and transient sig-
nificant decrease in IL-13 mRNA levels in Jurkat T cells.
This decrease occurred without altering IL-13 mRNA
stability (Fig. 2b). Thus, the cell line was chosen as a
model of transfection assay for studying the effect of
TGF-β on IL-13 production by normal T lymphocytes.
To ascertain that TGF-β acts at the transcriptional level
to inhibit IL-13 production, Jurkat T cells were
Fig. 2 (See legend on next page.)
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Fig. 2 Transforming growth factor (TGF)-β modulates interleukin (IL)-13 mRNA steady-state levels by acting on IL-13 gene transcription. a Jurkat T
cells were cultured in 0.5 % fetal calf serum (FCS)-containing medium for 16 h before addition of human recombinant TGF-β for the indicated
time periods. IL-13 mRNA expression was measured by RT-PCR. The results are presented as mean percentage (±SD) of IL-13 expression measured
in the presence of TGF-β (dark bars) relative to the respective IL-13 expression detected at the same time in the absence of TGF-β (white bars)
and reported to 100 to allow comparison between time arrests. The results are representative of three independent experiments. *p < 0.05;
**p < 0.01. b Following culture in 0.5 % FCS-containing medium for 16 h, Jurkat T cells were treated with (dark dots) and without (white dots)
TGF-β for 4 h. In order to stop ongoing transcription, actinomycin D was then added (squares) or not (triangles) for a 1-, 3- and 5-h further incubation.
IL-13 mRNA expression was analyzed by quantitative RT-PCR. The results are presented as comparative cycle threshold (ΔCt), an arbitrary value from
three independent experiments. c Jurkat T cells were transfected with pGL3 2666-bp IL-13 promoter construct/Luciferase (2666 bp-IL-13-Lux)
promoter-containing plasmid. Cells were then treated (dark bars) or not (white bars) with TGF-β in 0.5 % FCS-containing medium for 24 h. The results
are presented as mean percentage (±SD) of 2666 bp-IL13-Lux promoter activity detected in the presence of TGF-β relative to respective activity
without TGF-β and reported to 100. The results are representative of six independent experiments. ***p < 0.001
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(2666 bp-IL13-Lux). As presented in Fig. 2c, TGF-β ex-
posure induced a significant decrease in IL-13 promoter
luciferase activity compared with cells that were not
exposed to TGF-β, with a mean inhibition of 40 ± 10 %
(n = 6; p < 0.001). These data clearly indicate that TGF-β
modulates IL-13 mRNA steady-state levels by acting on
gene transcription.
Involvement of Smad- and MAPK-dependent mechanisms
The mechanisms by which TGF-β alters IL-13 synthesis
could involve either TGF-β receptor expression or several
signaling pathways, including Smad and MAPK. First, the
differences in responses of T lymphocytes from healthy
donors and patients with SSc were not linked to an alter-
ation in TGF-β receptor level expression, because TGFβRI
and TGFβRII mRNA expression in resting PBLs from
healthy donors and patients with SSc was not significantly
different (Fig. 3a), nor was the membrane expression de-
tected by FACS analysis (data not shown). In regard to
Smad pathway activation, TGF-β induced a rapid and sus-
tained phosphorylation of Smad3 molecules in T lympho-
cytes from patients with SSc that was more intense than
observed in T lymphocytes from healthy donors and in
Jurkat T cells, although with no significant difference
when we considered the nine patients with SSc (Fig. 3b).
The TGF-β–induced Smad3 phosphorylation in PBLs
from patients with SSc (Fig. 3b, left panel) was decreased
in the presence of a specific Smad3 inhibitor (SIS3), al-
though to a lesser extent than the decrease observed in T
lymphocytes from healthy donors and in Jurkat T cells
(Fig. 3b, middle and right panels, respectively). Moreover,
the increase in IL-13 mRNA levels induced by TGF-β ob-
served in patients with SSc (Fig. 3c, left panel) was par-
tially reversed in the presence of SIS3, and, conversely, the
decrease in IL-13 mRNA levels induced by TGF-β in PBLs
from healthy donors and Jurkat T cells was totally reversed
(Fig. 3c, right panels).
The ability of TGF-β to activate the Smad3/4 tran-
scriptional activity was assessed by transfection assay of
the Jurkat cell line with the Smad3/4-specific reporterconstruct ([CAGA]9-Lux). As shown in Fig. 3d, TGF-β
induced a significant mean fold increase of 1.54 ± 0.17
(n = 4; p < 0.01) in transactivation of the (CAGA)9-Lux
promoter after 24 h of exposure. This was reversed by
cotransfection of the (CAGA)9-Lux promoter with a dom-
inant negative of Smad3 (ΔNSmad3) or the addition of
SIS3 (Fig. 3d). Of interest, addition of SIS3 or overexpres-
sion of ΔNSmad3 totally reversed TGF-β-induced inhib-
ition of IL-13 promoter activity in Jurkat T cells (Fig. 3e),
clearly demonstrating involvement of the Smad pathway in
TGF-β-induced modulation of IL-13 expression in T cells.
Altogether, these results indicate that the TGF-β-
induced Smad pathway is involved in stimulation of
IL-13 expression by TGF-β in T lymphocytes from pa-
tients with SSc and, according to the effect of SIS3,
might be more activable in T lymphocytes from patients
with SSc than from healthy donors.
The p38 pathway regulates several Th2 cytokines in-
cluding IL-13 [20] and the activation of p38 pathway
downstream of TGF-β receptors can potentially regulate
GATA-3/IL-13 expression [21]. Our results show that
TGF-β did activate the p38 pathway in T cells because
TGF-β induced a rapid and prolonged phosphorylation
of p38 (data not shown). The role of the p38 pathway in
TGF-β-induced IL-13 synthesis was investigated by
using a specific p38 inhibitor (SB203580). As shown in
Fig. 4a, both the addition of either an ALK5 inhibitor
(SB431542) or SB203580 reversed the increased level of
IL-13 mRNA transcripts detected in the presence of
TGF-β in PBLs from patients with SSc. Both inhibitors
also reversed the inhibitory effect of TGF-β on IL-13
mRNA expression in healthy donors (Fig. 4b), as well as
in the Jurkat cell line (Fig. 4c, left panel). The role of the
p38 pathway in IL-13 gene expression was investigated
using transfected Jurkat T cells, and our results show that
the addition of SB431542 or SB203580 reversed the effect
of TGF-β on IL-13 promoter activity, as well as on IL-13
mRNA transcripts (Fig. 4c, right panel).
The effects of SB431542 and SB203580 on Smad path-
way activation were studied in PBLs from patients with
SSc by Western blot analysis. As expected, the ALK5
Fig. 3 (See legend on next page.)
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Fig. 3 Transforming growth factor (TGF)-β increases interleukin (IL)-13 expression in the peripheral blood lymphocytes (PBLs) of patients with
systemic sclerosis (SSc) via a Smad-dependent mechanism. a Type I TGF-β transmembrane receptor (TGF-βR1) and TGF-βR2 mRNA levels were
measured by RT-PCR analysis in resting PBLs from healthy donors (n = 7) and patients with SSc (n = 11). b and c PBLs from patients with SSc
(left panel) and healthy donors (middle panel) as Jurkat T cells (right panel) were cultured in 0.5 % fetal calf serum (FCS)-containing medium and treated
with a specific Smad3 inhibitor (SIS3) for 1 h before addition of TGF-β or not for 4 h. b Expression of phosphorylated Smad3, nonphosphorylated
Smad3 and β-actin was assessed by Western blotting. Semiquantitative analysis was performed by using ImageJ software, with β-actin levels used for
normalization. Normalized data are schematized as bars under the Western blots. c Expression of IL-13 mRNA was measured by quantitative RT-PCR.
The results are presented as mean percentage (±SD) of IL-13 expression detected in the presence of TGF-β (dark bars) relative to the respective IL-13
expression without TGF-β (white bars) and reported to 100 to allow comparison. d and e Jurkat T cells were transfected with d (CAGA)9-Lux or
e pGL3 2666-bp IL-13 promoter construct/Luciferase (2666 bp-IL13-Lux) . Cells were then treated (dark bars) or not (white bars) with TGF-β in 0.5 %
FCS-containing medium for 24 h. Jurkat T cells transfected with (CAGA)9-Lux d or 2666 bp-IL13-Lux promoter (e) were treated with or without SIS3 1 h
before adding (or not) TGF-β (middle double bars). Jurkat T cells were cotransfected with c (CAGA)9-Lux promoter and a dominant negative of Smad3
(ΔNSmad3) or e 2666 bp-IL13-Lux promoter and ΔNSmad3, and then Jurkat cells were treated with or without TGF-β (right double bars). The results are
presented as mean percentage (±SD) of (CAGA)9-Lux or 2666 bp-IL13-Lux promoter activity detected in the presence of TGF-β (dark bars) relative to
respective activity without TGF-β (white bars) and reported to 100 to allow comparison. b–e Results are representative of four independent
experiments. **p < 0.01; ***p < 0.001
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Smad3 phosphorylation in PBLs from patients with SSc
and healthy donors, as well as in Jurkat T cells (Fig. 4d).
Interestingly, the p38 inhibitor partially decreased TGF-β-
induced Smad3 phosphorylation in SSc T cells, whereas it
totally inhibited Smad3 phosphorylation in healthy donors
(Fig. 4d).
Altogether, these results demonstrate a cooperative role
between Smad and p38-MAPK signaling in mediating
TGF-β-induced upregulation of IL-13 expression in T
lymphocytes from patients with SSc.
Upregulation of IL-13 gene expression by TGF-β occurs
via GATA-3 transcription factor regulation: implication of
Smad3 and MAPK signaling pathways
Because GATA-3 has been shown to activate both
mouse [44] and human [45] IL-13 promoters, respect-
ively, in splenic T lymphocytes and Jurkat T cells, and
because TGF-β was shown to inhibit Th2 differentiation
via repression of the transcription factor GATA-3 [24],
we hypothesized that GATA-3 could be differentially
modulated by TGF-β in PBLs from patients with SSc
and healthy donors and could be responsible for the ef-
fects of TGF-β on IL-13 expression. Basal GATA-3
mRNA levels were compared in PBLs from patients with
SSc and healthy donors, and no differences were observed
(Fig. 5a). To determine whether GATA-3 was involved in
TGF-β-induced modulation of IL-13 expression, Jurkat T
cells were transfected with a small interfering RNA
(siRNA), which specifically targeted GATA-3 mRNA and
specifically downregulated GATA-3 protein expression, as
shown in Fig. 5b (right panel). Cotransfection of Jurkat T
cells with 2666 bp-IL13-Lux plasmid and GATA-3 siRNA
induced a significant inhibition of IL-13 promoter activity
and reversed the inhibitory effect of TGF-β. This clearly
indicates that GATA-3 is involved in both IL-13 synthesis
and TGF-β inhibitory effects. To determine whether
TGF-β had a specific, direct effect on GATA-3 expressionin T cells, GATA-3 nuclear protein expression after incu-
bation with TGF-β was assessed by Western blot analysis.
As shown in Fig. 5c, GATA-3 expression was not modu-
lated in PBLs from patients with SSc (left panel), whereas
it was decreased in response to TGF-β in healthy donors
(middle panel) and Jurkat T cells (right panel). The role of
both the Smad and MAPK pathways in GATA-3 expres-
sion was investigated, and the results shown in Fig. 5c in-
dicated that SB431542, SIS3 and SB203580 did not affect
GATA-3 expression in PBLs from patients with SSc (left
panel). In contrast, these inhibitors reversed the TGF-β ef-
fect on GATA-3 inhibition in PBLs from healthy donors
and in Jurkat T cells with even an increase after ALK5
inhibitor addition (middle and right panels). This could
suggest that GATA-3 nuclear translocation might be con-
trolled by Smad-dependent factors.
To assess the involvement of the GATA-3 transcription
factor in the regulation of the IL-13 gene by TGF-β, chro-
matin was extracted from T cells and immunoprecipitated
with anti-GATA-3 antibody. PCR amplification revealed
GATA-3 enrichment in the IL-13 promoter gene by chro-
matin immunoprecipitation (ChIP) as compared with a
negative KRT1 promoter gene control and two positive
genes, SERPINF1 and CXCL4, in PBLs and Jurkat T cells
(Fig. 5d, left panel). The effect of TGF-β on the capacity of
GATA-3 to bind to the IL-13 promoter was investigated
after cell treatment with TGF-β for 4 h. As shown in
Fig. 5d (right panel), TGF-β decreased GATA-3 ChIP en-
richment of IL-13 gene in Jurkat T cells by 74 ± 24 % and
29 ± 12 % after 30 min and 4 h of treatment, respectively.
Furthermore, our data show that TGF-β increased
GATA-3 ChIP enrichment of the IL-13 gene by 336 ± 70 %
(n = 3; p < 0.01) in PBLs from patients with SSc (Fig. 5e, left
panel), whereas TGF-β decreased GATA-3 ChIP enrich-
ment of the IL-13 gene by 70 ± 6 % (n = 3; p < 0.01) in PBLs
from healthy donors (Fig. 5e, right panel).
Overall, GATA-3 binding capacity on IL-13 promoter
was increased in patients with SSc and decreased in
Fig. 4 Implication of the p38 mitogen-activated protein kinase pathway downstream of transforming growth factor (TGF)-β receptors on peripheral
blood lymphocytes (PBLs). PBLs from a patients with SSc and b healthy donors were treated with (or without) SB431542 (activin receptor-like kinase
ALK5 inhibitor) or SB203580 (specific p38 inhibitor) for 1 h before the adding, or not, TGF-β. Interleukin (IL)-13 mRNA expression was measured by
RT-PCR. The results are presented as mean percentage (±SD) of IL-13 expression detected in the presence (dark bars) or absence (white bars) of TGF-β
relative to basal IL-13 expression taken as 100. c After 16 h of culture in 0.5 % fetal calf serum (FCS)-containing medium, Jurkat T cells were treated with
(or without) SB431542 or SB203580 for 1 h before adding, or not, TGF-β, and IL-13 mRNA expression was measured by RT-PCR (left panel). Jurkat T cells
were transfected with pGL3 2666-bp IL-13 promoter construct/Luciferase (2666 bp-IL13-Lux) or empty pGL3-Lux promoter and then treated or not with
SB431542 or SB203580 for 1 h before adding TGF-β (dark bars) or not (white bars) for a further 24-h culture in 0.5 % FCS-containing medium (right panel).
The results are presented as mean percentage (±SD) of IL-13 expression (left panel) or 2666 bp-IL13-Lux promoter activity (right panel) detected in the
presence (dark bars) or absence (white bars) of TGF-β relative to basal IL-13 expression taken as 100. The results shown in a–c are representative of four
independent experiments. *p< 0.05; ***p < 0.001. d Phosphorylated Smad3 and respective nonphosphorylated protein expression was detected by
Western blotting in PBLs from patients with SSc (left panel), healthy donors (middle panel) and Jurkat T cells (right panel) cultured in 0.5 % FCS-containing
medium with SB431542 or SB203580 for 1 h before addition of TGF-β or not for 4 h. The results are representative of four independent experiments.
Semiquantitative analysis of blots was performed by using ImageJ software with Smad3 levels for normalization. Normalized data are schematized as bars
under the Western blots
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Fig. 5 Upregulation of interleukin (IL)-13 gene expression by transforming growth factor (TGF)-β occurs via GATA-3 transcription factor regulation:
implication of Smad3 and mitogen-activated protein kinase (MAPK) signaling pathways. a GATA-3 mRNA levels in peripheral blood lymphocytes
(PBLs) from patients with systemic sclerosis (SSc) (n = 11) and healthy donors (n = 8) were measured by RT-PCR analysis. b Jurkat T cells were
cotransfected with pGL3 2666-bp IL-13 promoter construct/Luciferase (2666 bp-IL13-Lux) promoter and either a small interfering RNA (siRNA)
specific for GATA-3 or siRNA control. Jurkat transfected cells were then treated or not with TGF-β for 24 h in 0.5 % fetal calf serum (FCS)-containing
medium. The results are presented as mean percentage (±SD) of 2666 bp-IL13-Lux promoter activity in the presence (dark bars) or absence (white bars)
of TGF-β relative to control siRNA activity without TGF-β taken as 100 (left panel). Expression of GATA-3 and β-actin in total lysates from control or
GATA-3 siRNA was measured by Western blotting (right panel). The results are representative of three independent experiments. **p < 0.01. c Expression
of GATA-3 and β-actin was measured by Western blotting in nuclear lysates from patients with SSc (left panel), healthy donors (middle panel) and
Jurkat T cells (right panel) cultured in 0.5 % FCS-containing medium with SB431542 (activin receptor-like kinase ALK5 inhibitor), specific Smad3 inhibitor
(SIS3) or SB203580 (specific p38 inhibitor) for 1 h before addition of TGF-β for 4 h. The results are representative of four independent experiments.
Semiquantitative analysis of the blots was performed by using ImageJ software with β-actin levels for normalization. Normalized data are schematized
as bars under the Western blots. d Jurkat T cells were cultured in 0.5 % FCS- containing medium for 16 h before addition of human recombinant
TGF-β for 4 h (left panel) or for 30 min or 4 h (right panel). e PBLs from patients with SSc (n = 3) (left panel) and healthy donors (n = 3) (right panel)
were stimulated with anti-CD3/anti-CD28 antibodies and IL-2 for 5 days and then treated or not with TGF-β for the last 4 h. d and e After precipitation
of the protein–DNA complexes with specific antibody to GATA-3 or control immunoglobulin G (IgG), PCR amplification of the IL-13 fragment was
performed using IL-13 promoter primers. GATA-3 chromatin immunoprecipitation (ChIP) enrichment = ChIP/input × 100 was determined by quantitative
RT-PCR. The results are presented as mean (±SD) GATA-3 ChIP enrichment (GATA-3/IgG ratio) in the IL-13 gene after 4-h incubation with TGF-β (dark
bars) and relative to respective expression in the absence of TGF-β (white bars) and reported to 100 to allow comparison of enrichment. The amplified
SERPINF1 and CXCL4 promoter regions were used as positive controls for GATA-3 binding in Jurkat T-cells. *p < 0.05, **p < 0.01
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absence of GATA-3 downregulation by TGF-β, and con-
versely its increase, explained the overexpression of
IL-13 expression in patients with SSc.
Discussion
The pathogenesis of SSc is not completely elucidated
and includes abnormal immune system activation; how-
ever, the pathways active in the effector mechanisms are
still not completely understood. As TGF-β and IL-13
have been depicted as key mediators in the pathogenesis
of SSc, our concern in the present study was to assess
the precise role of TGF-β in IL-13 expression in T lym-
phocytes of patients with SSc. The present study eluci-
dates a new aspect of the pathogenic role of TGF-β in
SSc by showing upregulation of IL-13 synthesis in re-
sponse to TGF-β in the peripheral CD4+ and CD8+ T
cells of patients with SSc, whereas IL-13 expression was
downregulated by TGF-β in healthy donors.
Higher IL-13 production by peripheral blood [36] and
skin biopsy [10] CD8+ T cells had previously shown that
SSc is associated with IL-13 dysregulation. Accordingly,
our results allowed us to demonstrate for the first time a
relationship between increase IL-13 production in CD4+
and CD8+ T cells and TGF-β signaling in patients with
SSc, and they enabled us to further identify mechanisms
involved in this dysregulation.
In spite of the fact that TGF-β is a key mediator in the
pathological tissue fibrosis in many diseases [23], TGF-β
is also known as a potent physiological immunomodula-
tor in mammals that is able to inhibit Th2 and Th1
differentiation by repressing activation of GATA-3 and
T-bet transcription factors, respectively [23]. GATA-3
has been recognized as the main transcription factorregulating IL-13 gene expression in T cells [35, 38], and
it has also been associated with IL-13 overproduction in
patients with SSc [40]. The present study did not allow
us to set up GATA-3 as a potent biomarker of immune
dysfunction in SSc, as previously described by Medsger
et al. [40]. Our results show that TGF-β was able to
regulate GATA-3 ChIP enrichment of the IL-13 gene,
resulting in the respective stimulation or inhibition of
IL-13 expression in patients with SSc and in healthy do-
nors. This is in contrast to the findings of Medsger and
colleagues, who described that IL-13 overproduction by
naïve CD8+ T cells from patients with SSc was related to
GATA-3 dysregulation [40], whereas we detected similar
levels of GATA-3 mRNA expression in patients with SSc
and healthy donors. This difference may be explained
by the use of whole T-cell populations in our study,
whereas Medsger et al. used isolated CD8+ T cells.
However, the mechanism involved in GATA-3 dys-
regulation remained to be elucidated. Our results show
that IL-13 gene regulation by TGF-β occurs via Smad-
and p38-dependent pathways and that both of these
pathways are involved in GATA-3 modulation. The in-
volvement of the Smad pathway was demonstrated by
using the specific SIS3 inhibitor, which reversed the
TGF-β effects on IL-13 and GATA-3 expression. In ac-
cordance with our results, in vivo studies demonstrated
that Smad3-deficient mice exhibited increased IL-13
cytokine levels in association with an upregulation of
GATA-3 levels, suggesting that GATA-3 depends on
Smad3 expression for regulation of IL-13 synthesis [21].
In addition, GATA-3 has been shown to physically and
functionally interact with Smad3 to allow TGF-β regula-
tion of GATA-3 target genes [44]. GATA-3-mediated
activation of several cytokine promoters, including IL-4
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“friend of GATA” (FOG), which acts as a GATA-3 repres-
sor in naïve Th cells, and its downregulation is key for
Th2 cell development [45]. Functional interactions be-
tween FOG and GATA-3 mechanisms have not been de-
scribed, but FOG may interact with a specific corepressor,
mCtBP2 [46], suggesting that its downregulation might
favor upregulation of IL-13 expression in T cells of pa-
tients with SSc. We also demonstrated that the cross-talk
between MAPKs and Smad proteins modulates
TGF-β effects on T cells from patients with SSc. Indeed,
our data show that p38 inhibition reversed the effects of
TGF-β on GATA-3 and IL-13 expression and decreased
TGF-β-induced phosphorylation of Smad3. The role ofFig. 6 Schematic hypothesis about interleukin (IL)-13 synthesis induced thr
response to transforming growth factor (TGF)-β in T cells of patients with s
then recruits and phosphorylates the type I receptor (TβRI), leading to activ
The TβRI–TβRII complex then phosphorylates Smad 2/3 proteins, which comp
factors of target genes. In the non-Smad pathway, the TβRI–TβRII complex tra
signal-regulated kinase (Ras-ERK) pathway, TGF-β-activated kinase (TAK), c-Jun
factors translocate to the nucleus and regulate the expression of target genes
occurs via GATA-3 transcription factor modulation through Smad3 and p38-M
SIS3 or by the specific p38 inhibitor SB203580, respectively. Additionally, the A
phosphorylation. CBP CREB-binding protein, COL1A collagen type I alpha, MCP
α-SMA α-smooth muscle actinthe p38-MAPK pathway in regulating GATA-3 phos-
phorylation and Th2 cytokine gene expression has been
highlighted in two previous studies, evidencing that
GATA-3 phosphorylation by p38-MAPK facilitates nuclear
translocation and allows regulation of the IL-5, IL-4 and
IL-13 genes [47, 48].
To schematize the results of our present work, we
propose a mechanistic scheme with signaling pathways
involved in TGF-β-induced IL-13 synthesis in T lympho-
cytes of patients with SSc (Fig. 6).
Multiple factors, including cellular interactions, T-cell
receptor signals, cytokines and transcription factors,
could cooperate with TGF-β to influence the IL-13 re-
sponse in patients with SSc. In particular, high levels ofough Smad and mitogen-activated protein kinase (MAPK) pathways in
ystemic sclerosis. TGF-β binds first to its type II receptor (TβRII), which
in receptor-like kinase (ALK5) activation within the receptor complex.
lex with Smad4 to accumulate in the nucleus and act as transcription
nsmits its signal through other factors, such as by the Ras-extracellular
N-terminal kinase (JNK) and p38-MAPK pathways. Under activation, these
. We observed that the upregulated IL-13 expression induced by TGF-β
APK signaling pathways, which is reversed by the specific Smad3 inhibitor
LK5-specific inhibition by SB431542 abolishes the TGF-β-induced Smad3
-1 monocyte chemoattractant protein 1, SBE Smad-binding element,
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responsible for stimulation of the GATA-3 [49] or Smad
[50] pathway, respectively. In addition, T-bet transcription
factor polymorphisms have been described in SSc [51]. As
this factor is able to regulate IL-13 synthesis via GATA-3
repression in healthy individuals [52], its alteration could
be involved in the upregulation of GATA-3 observed in
the IL-13 promoter in T cells of patients with SSc. In this
context, recent studies of GATA-3 as a therapeutic target
in allergic and inflammatory diseases are being developed,
including various animal models and clinical applications.
The GATA-3-specific inhibitor DNAzyme hgd40 is al-
ready being tested in clinical trials (www.clinicaltrials.gov)
to treat allergic asthma (NCT01743768) and ulcerative
colitis (NCT02129439). It could thus be readily available
for trials in patients with SSc after any antifibrotic poten-
tial of this new specific inhibitor has been confirmed in
animal models of SSc.
Conclusions
In summary, our results provide new evidence about the
active contribution of Smad and p38 pathways down-
stream to TGF-β, leading to regulation of GATA-3 func-
tions and stimulation of IL-13 synthesis in T lymphocytes
of patients with SSc. GATA-3 might be considered as a
potential target for new therapies, and prevention of its
interaction with other factors by inhibiting p38-MAPK or
Smad3 pathways may provide a new approach for the
treatment of SSc.
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